Protocol Ledger

NCT06079983 · Phase III · RECRUITING

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Interventional Phase III clinical trial protocol NCT06079983 sponsored by Jiangsu Alphamab Biopharmaceuticals Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-01 Enrollment: 400 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06079983
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)400 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06079983
Protocol FieldVerified Registry Value
NCT IdentifierNCT06079983
Consolidated Lead SponsorJiangsu Alphamab Biopharmaceuticals Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment400 participants (ESTIMATED)
Registered Start Date2023-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06079983
Hospital Research SiteLocationSite Profile
Affiliated Hospital of Hebei UniversityBaoding, ChinaOpen Hospital Dossier ->
Cancer Hospital Chinese Academy of Medical SciencesBeijing, ChinaOpen Hospital Dossier ->
Peking University Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI